Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $412.9 million.

  • Entrada Therapeutics' Liabilities and Shareholders Equity fell 2554.9% to $412.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 1143.86%. This contributed to the annual value of $526.3 million for FY2024, which is 1217.6% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Liabilities and Shareholders Equity is $412.9 million, which was down 2554.9% from $448.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Liabilities and Shareholders Equity registered a high of $582.0 million during Q2 2024, and its lowest value of $252.1 million during Q4 2022.
  • Its 4-year average for Liabilities and Shareholders Equity is $439.0 million, with a median of $475.6 million in 2023.
  • Per our database at Business Quant, Entrada Therapeutics' Liabilities and Shareholders Equity surged by 8614.59% in 2023 and then plummeted by 2554.9% in 2025.
  • Entrada Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $252.1 million in 2022, then surged by 86.15% to $469.2 million in 2023, then increased by 12.18% to $526.3 million in 2024, then decreased by 21.55% to $412.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $412.9 million in Q3 2025, compared to $448.8 million in Q2 2025 and $486.5 million in Q1 2025.